4.7 Article Proceedings Paper

Transport, stability, and biological activity of resveratrol

期刊

RESVERATROL AND HEALTH
卷 1215, 期 -, 页码 48-59

出版社

WILEY-BLACKWELL
DOI: 10.1111/j.1749-6632.2010.05871.x

关键词

resveratrol; transport; stability; resveratrol analogues; metabolites; biotransformation

资金

  1. Conseil Regional de Bourgogne
  2. Ligue Bourguignone contre le Cancer (especially Nievre committee)
  3. ANR [P008641]

向作者/读者索取更多资源

Numerous studies have reported interesting properties of trans-resveratrol, a phytoalexin, as a preventive agent of several important pathologies: vascular diseases, cancers, viral infections, and neurodegenerative processes. These beneficial effects of resveratrol have been supported by observations at the cellular and molecular levels in both cellular and in vivo models, but the cellular fate of resveratrol remains unclear. We suggest here that resveratrol uptake, metabolism, and stability of the parent molecule could influence the biological effects of resveratrol. It appears that resveratrol stability involves redox reactions and biotransformation that influence its antioxidant properties. Resveratrol's pharmacokinetics and metabolism represent other important issues, notably, the putative effects of its metabolites on pathology models. For example, some metabolites, mainly sulfate-conjugated resveratrol, show biological effects in cellular models. The modifications of resveratrol stability, chemical structure, and metabolism could change its cellular and molecular targets and could be crucial for improving or decreasing its chemopreventive properties.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Gastroenterology & Hepatology

Helicobacter pylori infection has a detrimental impact on the efficacy of cancer immunotherapies

Paul Oster, Laurie Vaillant, Erika Riva, Brynn McMillan, Christina Begka, Caroline Truntzer, Corentin Richard, Marine M. Leblond, Meriem Messaoudene, Elisavet Machremi, Emeric Limagne, Francois Ghiringhelli, Bertrand Routy, Gregory Verdeil, Dominique Velin

Summary: This study revealed that Helicobacter pylori infection may reduce the efficacy of cancer immunotherapies, as demonstrated in mouse models and human clinical studies.
Article Oncology

MEK inhibition overcomes chemoimmunotherapy resistance by inducing CXCL10 in cancer cells

Emeric Limagne, Lisa Nuttin, Marion Thibaudin, Elise Jacquin, Romain Aucagne, Marjorie Bon, Solene Revy, Robby Barnestein, Elise Ballot, Caroline Truntzer, Valentin Derangere, Jean-David Fumet, Charlene Latour, Cedric Rebe, Pierre-Simon Bellaye, Coureche-Guillaume Kaderbhai, Aodrenn Spill, Bertrand Collin, Mary B. Callanan, Aurelie Lagrange, Laure Favier, Bruno Coudert, Laurent Arnould, Sylvain Ladoire, Bertrand Routy, Philippe Joubert, Francois Ghiringhelli

Summary: Chemotherapy combined with MEK inhibitor enhances the sensitivity of lung cancer cells to immune checkpoint inhibitors by inducing CXCL10 expression and CD8(+) T cell recruitment. The study also highlights the role of TLR9- and OPTN-dependent mitophagy in enhancing the efficacy of chemoimmunotherapy.

CANCER CELL (2022)

Article Oncology

Modified FOLFIRINOX Versus CISGEM Chemotherapy for Patients With Advanced Biliary Tract Cancer (PRODIGE 38 AMEBICA): A Randomized Phase II Study

Jean marc Phelip, Jerome Desrame, Julien Edeline, Emilie Barbier, Eric Terrebonne, Pierre Michel, Herve Perrier, Laetitia Dahan, Vincent Bourgeois, Faiza Khemissa Akouz, Emilie Soularue, Valerie Lebrun Ly, Yann Molin, Thierry Lecomte, Francois Ghiringhelli, Romain Coriat, Samy Louafi, Cindy Neuzillet, Sylvain Manfredi, David Malka

Summary: This study compared triplet chemotherapy with doublet chemotherapy in advanced biliary tract cancer treatment, with the results showing triplet chemotherapy did not meet the primary study endpoint. Doublet chemotherapy remains the first-line standard in advanced BTC.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Article Oncology

A Natural Polyphenol Exerts Antitumor Activity and Circumvents Anti-PD-1 Resistance through Effects on the Gut Microbiota

Meriem Messaoudene, Reilly Pidgeon, Corentin Richard, Mayra Ponce, Khoudia Diop, Myriam Benlaifaoui, Alexis Nolin-Lapalme, Florent Cauchois, Julie Malo, Wiam Belkaid, Stephane Isnard, Yves Fradet, Lharbi Dridi, Dominique Velin, Paul Oster, Didier Raoult, Francois Ghiringhelli, Romain Boidot, Sandy Chevrier, David T. Kysela, Yves Brun, Emilia Liana Falcone, Genevieve Pilon, Florian Plaza Onate, Oscar Gitton-Quent, Emmanuelle Le Chatelier, Sylvere Durand, Guido Kroemer, Arielle Elkrief, Andre Marette, Bastien Castagner, Bertrand Routy

Summary: The study demonstrates that oral supplementation with polyphenol-rich berry camu-camu alters gut microbial composition in mice, leading to antitumor activity and enhanced anti-PD-1 response. The active compound castalagin enriches for specific bacteria and induces metabolic changes to support immunotherapy efficacy.

CANCER DISCOVERY (2022)

Editorial Material Cell Biology

Mitophagy: a new actor in the efficacy of chemo-immunotherapy

Emeric Limagne, Francois Ghiringhelli

Summary: This study reveals the role of MAPK in chemo-immunotherapy and suggests that inhibition of MAPK pathway could enhance cancer cell mitophagy and improve the efficacy of immunotherapy.

AUTOPHAGY (2022)

Article Oncology

Targeting PD-L1 and TIGIT could restore intratumoral CD8 T cell function in human colorectal cancer

Marion Thibaudin, Emeric Limagne, Lea Hampe, Elise Ballot, Caroline Truntzer, Francois Ghiringhelli

Summary: The combination of atezolizumab and tiragolumab shows potential in reactivating the immune response in microsatellite stable colorectal cancers (MSS-CRC), especially in patients with higher baseline cell frequency and CD96 expression.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2022)

Article Biochemistry & Molecular Biology

Association of Anti-EGFR Antibody and MEK Inhibitor in Gynecological Cancer Harboring RAS Mutation: A Case Series

Julie Niogret, Valentin Derangere, Corentin Richard, Lisa Nuttin, Francois Ghiringhelli, Laure Favier, Leila Bengrine Lefevre, Anthony Bergeron, Laurent Arnould, Romain Boidot

Summary: Low-grade serous carcinoma is a less common subtype of serous carcinoma with better prognosis but poor response to chemotherapy. This study aims to evaluate the clinical benefit of MEK inhibitors in the management of advanced-stage low-grade serous carcinoma with KRAS or NRAS mutation. The results showed that MEK inhibitors, in combination with anti-EGFR antibody, provided disease stabilization in patients with RAS-mutated low-grade serous carcinoma. RB1 loss-of-function mutation may be a mechanism of resistance to MEK inhibitors in these patients.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

Article Oncology

Management and Outcomes of Pancreatic Cancer in French Real-World Clinical Practice

Valerie Jooste, Leila Bengrine-Lefevre, Sylvain Manfredi, Valerie Quipourt, Pascale Grosclaude, Olivier Facy, Come Lepage, Francois Ghiringhelli, Anne-Marie Bouvier

Summary: Real-world data on the management and outcomes of pancreatic cancer showed that only half of elderly patients aged 75-84 with a surgically resectable tumor actually underwent resection, and a significant percentage of patients aged >= 85 refused chemotherapy, highlighting the need for expanded geriatric assessments.

CANCERS (2022)

Review Cell Biology

Impact of Glucocorticoid Use in Oncology in the Immunotherapy Era

Laura Kalfeist, Loick Galland, Fanny Ledys, Francois Ghiringhelli, Emeric Limagne, Sylvain Ladoire

Summary: Glucocorticoids are widely prescribed drugs in cancer patients due to their anti-inflammatory, anti-oedema, and anti-allergy properties. They are used in various clinical situations in oncology, including managing cancer-related symptoms and preventing or treating side effects or immune-related adverse events of anti-cancer therapies. Moreover, glucocorticoids have been found to affect immune response and tumor efficacy.
Review Cell Biology

Tumor Immunogenic Cell Death as a Mediator of Intratumor CD8 T-Cell Recruitment

Nicolas Roussot, Francois Ghiringhelli, Cedric Rebe

Summary: The success of anticancer treatments depends on the ability of dying cancer cells under chemotherapy or physical stress to activate immune cells and stimulate an antitumor response. This can be achieved through the release of danger-associated molecular patterns (DAMPs) and the recruitment of CD8 T cells. However, the effectiveness of immune checkpoint blockers in reversing T-cell exhaustion is dependent on the recruitment of CD8 T cells within the tumor. Chemokines play a crucial role in CD8 T-cell recruitment. This review aims to explore the role of chemokines released during immunogenic cell death (ICD) in CD8 T-cell recruitment and antitumor response, as well as their potential clinical applications.
Review Oncology

Clinical Utility of Genomic Tests Evaluating Homologous Recombination Repair Deficiency (HRD) for Treatment Decisions in Early and Metastatic Breast Cancer

Loick Galland, Nicolas Roussot, Isabelle Desmoulins, Didier Mayeur, Coureche Kaderbhai, Silvia Ilie, Audrey Hennequin, Manon Reda, Juliette Albuisson, Laurent Arnould, Romain Boidot, Caroline Truntzer, Francois Ghiringhelli, Sylvain Ladoire

Summary: Breast cancer is the most common cancer in the world, and advancements in technology allow for the identification of specific molecular alterations in tumor cells, leading to new treatment options. This review summarizes the clinical utility of genomic tests in evaluating homologous recombination repair deficiency for breast cancer treatment decisions.

CANCERS (2023)

Article Oncology

GTN Enhances Antitumor Effects of Doxorubicin in TNBC by Targeting the Immunosuppressive Activity of PMN-MDSC

Nesrine Mabrouk, Cindy Racoeur, Jingxuan Shan, Aurelie Massot, Silvia Ghione, Malorie Privat, Lucile Dondaine, Elise Ballot, Caroline Truntzer, Romain Boidot, Francois Hermetet, Valentin Derangere, Melanie Bruchard, Frederique Vegran, Lotfi Chouchane, Francois Ghiringhelli, Ali Bettaieb, Catherine Paul

Summary: Our study aimed to test the beneficial effect of the nitric oxide donor glyceryltrinitrate (GTN) in combination with the chemotherapy drug doxorubicin in the treatment of triple-negative breast cancer (TNBC). Using a mouse model of TNBC, we found that the combination of the two drugs induced greater tumor regression compared to monotherapies, which was correlated with stronger activation of the immune system and a decrease in immunosuppressive immune cells. These findings suggest a new therapeutic perspective for TNBC treatment.

CANCERS (2023)

Article Cell Biology

Chrysin-Induced Regression of Angiogenesis via an Induction of DNA Damage Response and Oxidative Stress in In Vitro and In Vivo Models of Melanoma

Aicha Sassi, Maxime Fredon, Alexia K. Cotte, Camille Fuselier, Christophe Schneider, Laurent Martiny, David Monchaud, Leila Chekir-Ghedira, Virginie Aires, Dominique Delmas

Summary: Despite progress in treatments, melanoma incidence and mortality have increased. Chrysin, a natural polyphenol, shows potential as a therapeutic strategy due to its modulation of tumorigenesis and resistance mechanisms. This study reveals a link between chrysin-induced antitumoral effects, DNA damage pathway activation, and reduced angiogenesis in melanoma cells. The disruption of key protein actors in tumor growth by chrysin suggests its potential as a new therapeutic strategy in melanoma treatment.
Article Imaging Science & Photographic Technology

Predictive Factors of Local Recurrence after Colorectal Cancer Liver Metastases Thermal Ablation

Julien Odet, Julie Pellegrinelli, Olivier Varbedian, Caroline Truntzer, Marco Midulla, Francois Ghiringhelli, David Orry

Summary: This study aimed to identify risk factors for local recurrence (LR) after radiofrequency (RFA) and microwave (MWA) thermoablations (TA) of colorectal cancer liver metastases (CCLM). The size of the lesions and the nearby vessel were found to be significant risk factors for LR.

JOURNAL OF IMAGING (2023)

暂无数据